5734-66-7

Basic information

• Product Name: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)
• Synonyms: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI);2-AMINO-6-ETHYL-4(1H)-PYRIMIDINONE;4(1H)-Pyrimidinone, 2-amino-6-ethyl-;4(3H)-Pyrimidinone,2-amino-6-ethyl-;2-Amino-4-hydroxy-6-ethylpyrimidine;6-Ethylisocytosine;2-diazenyl-6-ethylpyrimidin-4-ol;2-Amino-6-ethylpyrimidin-4-ol
• CAS NO: 5734-66-7
• Molecular Formula: C₆H₉N₃O
• Molecular Weight: 139.15516
• Product Categories: PYRIMIDINE;Drug Intermediates
• Mol File: 5734-66-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 243-245 °C (decomp)
• Boiling Point: 265℃
• Flash Point: 114℃
• Appearance: /
• Density: 1.35
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.98±0.50(Predicted)
• CAS DataBase Reference: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)(5734-66-7)
• EPA Substance Registry System: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)(5734-66-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5734-66-7(Hazardous Substances Data)

Usage

Uses

2,6-Bis(2-pyridyl)-4(1H)-pyridone?belongs to pyrimidine derivatives and can be used as pharmaceutical intermediates.

InChI:InChI=1/C6H9N3O/c1-2-4-3-5(10)9-6(7)8-4/h3H,2H2,1H3,(H3,7,8,9,10)

Upstream product

• 593-85-1 diguanidine carbonate 
• 4949-44-4 ethyl propanoylacetate 
• 64-17-5 ethanol 
• 30414-53-0 methyl propanoyl acetate 
• 50-01-1 guanidine hydrochloride 

Downstream Products

• 5734-67-8 2-amino-4-chloro-6-ethylpyrimidine 
• 1393883-07-2 C₂₁H₁₉FN₆ 
• 1193-85-7 4-ethylpyrimidin-2-amine 
• 514854-13-8 2,4-diamino-6-ethyl-5-iodopyrimidine 
• 514854-15-0 2-amino-6-ethyl-4-methoxypyrimidine 
• 58-14-0 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine 
• 514854-12-7 2,4-diamino-6-ethylpyrimidine 
• 15043-03-5 6-ethylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H 4 receptor antagonists

This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

Quinolinyl pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents

NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

Pyrimidine Derivatives As HSP90 Inhibitors

The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or